iHuman (NYSE:IH - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.07 EPS for the quarter, Zacks reports. iHuman had a net margin of 10.69% and a return on equity of 10.57%.
iHuman Price Performance
Shares of NYSE IH opened at $2.38 on Thursday. The stock has a market capitalization of $123.81 million, a PE ratio of 9.15 and a beta of 0.36. The firm has a fifty day moving average of $2.26 and a 200-day moving average of $2.05. iHuman has a 52-week low of $1.47 and a 52-week high of $3.18.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in iHuman stock. Acadian Asset Management LLC bought a new position in shares of iHuman Inc. Sponsored ADR (NYSE:IH - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 15,067 shares of the company's stock, valued at approximately $32,000. 4.92% of the stock is owned by institutional investors and hedge funds.
About iHuman
(
Get Free Report)
iHuman Inc provides intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Reading, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, iHuman Writing, iHuman Fantastic Friends, and iHuman Readers; bekids Coding, bekids Coloring, bekids Reading, bekids Puzzle, bekids Academy, and Gogo Town; and Aha World, an open-ended interactive app that nurtures a desire for discovery.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iHuman, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iHuman wasn't on the list.
While iHuman currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
